Quick Links

Supported by City of Hope's NCI-funded Cancer Center Support Grant (CCSG)

 Developmental Cancer Therapeutics Program Publications, 2002

2006, 20052004, 2003, 2002

Beringer P, Aminimanizani A, Synold T, Scott C. Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. Ther Drug Monit; 2002, 24(2): 315-21.

Chen S. Modulation of aromatase activity and expression by environmental chemicals. Front Biosci; 2002; 7: d1712-9.

Chen S, Itoh T, Wu K, Zhou D, Yang C. Transcriptional regulation of aromatase expression in human breast tissue. J Steroid Biochem Mol Biol; 2002, 83(1-5): 93-9.

Chen S, Zhou D, Okubo T, Kao YC, Eng ET, Grube B, Kwon A, Yang C, Yu B. Prevention and treatment of breast cancer by suppressing aromatase activity and expression. Ann N Y Acad Sci; 2002; 963: 229-38.

Chen X, Shen B, Xia L, Khaletzkiy A, Chu D, Wong JY, Li JJ. Activation of nuclear factor kappaB in radioresistance of TP53-inactive human keratinocytes. Cancer Res; 2002, 62(4): 1213-21.

Eng ET, Williams D, Mandava U, Kirma N, Tekmal RR, Chen S. Anti-aromatase chemicals in red wine. Ann N Y Acad Sci; 2002; 963: 239-46.

Herzog JS, Jancis E, Liao S, Somlo G, Weitzel J. Restriction endonuclease fingerprinting enhanced conformation sensitive gel electrophoresis (REF-CSGS) in the analysis of BRAC1 Exong 11 mutations in a high risk breast cancer cohort. Human Mutation; 2002; 19: 656-663.

Lamont J, Kakuda JT, Smith DD, Wagman LD, Grannis FW. Systematic postoperative follow-up in patients with non-small lung cancer for detecting second primary lung cancer in stage 1A. Arch Surg; 2002; 137: 935-940.

Margolin K. Inhibition of vascular endothelial growth factor in the treatment of solid tumors. Curr Oncol Rep; 2002, 4(1): 20-8.

Margolin K, Atkins B, Thompson A, Ernstoff S, Weber J, Flaherty L, Clark I, Weiss G, Sosman J, I IS, Dutcher P, Gollob J, Longmate J, Johnson D. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol; 2002, 128(4): 214-8.

McCahill LE, Krouse R, Chu D, Juarez G, Uman GC, Ferrell B, Wagman LD. Indications and use of palliative surgery-results of Society of Surgical Oncology survey. Ann Surg Oncol; 2002, 9(1): 104-12.

McCahill LE, Krouse RS, Chu DZ, Juarez G, Uman GC, Ferrell BR, Wagman LD. Decision making in palliative surgery. J Am Coll Surg; 2002, 195(3): 411-22; discussi

Pezner RD, Chu DZ, Ellenhorn JD. Intraoperative radiation therapy for patients with recurrent rectal and sigmoid colon cancer in previously irradiated fields. Radiother Oncol; 2002, 64(1): 47-52.

Schwarz RE, Hillebrand G, Peralta EA, Chu D, Weiss LM. Long-term survival after radical operations for cancer treatment-induced sarcomas: How two survivors invite reflection on oncologic treatment concepts. Am J Clin Oncol; 2002, 25(3): 244-7.

Somlo G. Radical and simple mastectomy. N Engl J Med; 2002; 347: 2170-1.

Somlo G, Simpson JF, Frankel P, Chow W, Leong L, Margolin K, Morgan RJ, Raschko J, Shibata S, Forman S, Kogut N, McNamara M, Molina A, Somlo E, Doroshow JH. Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer. Br J Cancer; 2002, 87(3): 281-8.

Wagman LD. Fighting wars, winning battles. Ann Surg Oncol; 2002, 9(2): 115-6.

Wagman LD. "Necessary" transfusions and prognosis in gastric cancer. Ann Surg Oncol; 2002, 9(1): 1-2.

Yang C, Yu B, Zhou D, Chen S. Regulation of aromatase promoter activity in human breast tissue by nuclear receptors. Oncogene; 2002, 21(18): 2854-63.

Yen Y, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G, Twardowski P, Frankel P, Longmate J, Synold T, Newman EM, Lenz HJ, Gandara D, Doroshow JH. Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial. Cancer Chemother Pharmacol; 2002, 50(5): 353-9.

Zhang F, Zhou D, Kao YC, Ye J, Chen S. Expression and purification of a recombinant form of human aromatase from Escherichia coli. Biochem Pharmacol; 2002, 64(9): 1317-24.

Zhou B, Mo X, Liu X, Qiu W, Yen Y. Human ribonucleotide reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanism of drug resistance. Cytogenetics and Human Genetics; 2002, 95(1-2): 34-42.

Zhou B, Yen Y. Characterization of the human ribonucleotide reductase M2 subunit gene: Genomic structure and promoter analyses. Cytogenetics and Human Genetics; 2002, 9(1-2): 52-9.

Sadava D, Coleman A, Kane SE. Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. Journal of Liposome Research; 2002, 12(4): 301-9.

Coleman AB, Metz MZ, Donohue CA, Schwarz RE, Kane SE. Chemosensitization by fibroblast growth factor-2 is not dependent upon proliferation, S-phase accumulation, or p53 status. Biochemical Pharmacology; 2002, 64(7): 1111-23.

Sadava D, Ahn J, Zhan M, Pang M, Ding J, Kane SE. Effects of four Chinese herbal extracts on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. Cancer Chemotherapy & Pharmacology; 2002, 49(4): 261-6.

Sadava D, Phillips T, Lin C, Kane SE. Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Letters; 2002, 179(2): 151-6.

Davis ME, Bellocq NC. Cyclodextrin-containing polymers for gene delivery. Journal of Inclusion Phenomena and Macrocyclic Chemistry; 2002, 44(1-4): 17-22.

Popielarski SR, Mishra S, Davis ME. The effects of structure on gene delivery with linear beta- and gamma-cyclodextrin-containing polycations. Journal of Inclusion Phenomena and Macrocyclic Chemistry; 2002, 44(1-4): 453-457.

Pun SH, Davis ME. Development of a nonviral gene delivery vehicle for systemic application. Bioconjugate Chemistry; 2002, 13(3): 630-639.

Davis ME. Non-viral gene delivery systems. Current Opinion in Biotechnology; 2002, 13(2): 128-31.

Xu GR, Pan LX, Li H, Forman BM, Erickson SK, Shefer S, Bollineni J, Batta AK, Christie J, Wang TH, Michel J, Yang S, Tsai R, Lai L, Shimada K, Tint GS, Salen G. Regulation of the farnesoid X receptor (FXR) by bile acid flux in rabbits. Journal of Biological Chemistry; 2002, 277(52): 50491-50496.

 Search

Go!
Advanced Search Options
News & Publications Search
NCI CCC LogoCity of Hope is one of 40 Comprehensive Cancer Centers, the highest designation bestowed by the National Cancer Institute and a recognition of excellence in cancer treatment, research, prevention and education.
City of Hope strongly supports and values the uniqueness of all individuals and promotes a work environment where diversity is embraced.
NCI CCC LogoThe National Comprehensive Cancer Network®
(NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HON code of the Healthcare on the Net Foundation.